97170 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
Humanized anti-CD4 antibody with immunosuppressive properties
#302Virus coat protein/receptor chimeras and methods of use
#303Deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
#304METHODS AND COMPOSITIONS FOR THE INHIBITION OF HIV INFECTION OF T CELLS
#305Conjugate of an antibody against CD4 and antifusogenic peptides
#306Methods of treatment with glycosylated antibodies
#307Methods of treating lupus using CD4 antibodies
#308Antibody composition-producing cell in which enzyme expression is inhibited by RNAi
#309Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases
#310Vaccine
#311Antibody composition-producing cell with inactivated A-1,6-fusocyltransferase
#312Materials and methods to increase peptide chain expression
#313Env polypeptide complexes and methods of use
#314Compositions and methods of tolerizing a primate to an antigen
#315Naturally occurring IgM antibodies that bind lymphocytes
#316Optimized dosing with anti-CD4 antibodies for tolerance induction in primates
#317Molecular scaffolds for HIV-1 epitopes
#318PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE
#319Methods for enhancing the efficacy of IL-2 mediated immune responses
#320PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE
#321Methods of treating lupus using CD4 antibodies
#322Altered antibodies and their preparation
#323Method for Making Multispecific Antibodies Having Heteromultimeric and Common Components
#324Listeria-induced immunorecruitment and activation, and methods of use thereof
#325Method for making multispecific antibodies having heteromultimeric and common components
#326Suppression of transplant rejection
#327Methods for assaying inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion
#328Methods for predicting development of auto-immune diseases and treatment of same
#329Antibody Composition-Producing Cell
#330Method for treatment of malignant and infectious chronic diseases
#331Methods for distinguishing type-1 from type-2 diabetes
#332Compositions comprising a first agent which provides a primary activation signal to T cells and a second agent which stimulates an accessory molecule on the surface of T cells
#333Heterologous antibodies which bind human CD4
#334Vaccine adjuvant
#335Allogeneic and xenogeneic transplantation
#336Pharmaceutical compositions comprising an hiv envelope protein and cd4
#337Methods for assaying inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion
#338Identification and use of high efficacy vaccine antigens which modulate antigen presenting cells
#339Antibody composition-producing cell
#340Mammalian host cell modified by RNAi to inhibit α 1,6-fucosyltransferase
#341Methods and compositions for promoting immunopotentiation
#342Mono-and dual chemokine/cytokine constructs
#343Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes
#344Humanised antibodies
#345Humanised antibodies
#346Identification and use of high efficacy vaccine antigens which modulate antigen presenting cells
#347Antibody composition-producing cell
#348Antibody composition exhibiting increased cellular cytotoxicity due to glycosylation
#349Humanized anti-CD4 antibody with immunosuppressive properties
#350Human antibodies derived from immunized xenomice
#351Transgenic transchromosomal rodents for making human antibodies
#352Humanised antibodies
#353Transgenic transchromosomal rodents for making human antibodies
#354Methods for treating HIV infected subjects
#355Optimized dosing with anti-CD4 antibodies for tolerance induction in primates
#356Human antibodies derived from immunized xenomice
#357Antibody composition-producing cell
#358Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
#359Mutant Fab fragments of the chimeric 13B8.2 anti-CD4 antibody and their applications
#360Virus coat protein/receptor chimeras and method of use
#361Activation and expansion of cells
#362Humanised antibodies
#363Activation and expansion of cells
#364Humanised antibodies
#365Lipoparticles comprising proteins, methods of making, and using the same
#366Humanised antibodies
#367Specific depletion of cd4+ t cells
#368Generation of xenogeneic antibodies
#369Antibodies against T cells as therapeutics
#370Human antibodies derived from immunized xenomice
#371Anti-CD4 antibodies